Journal of Antimicrobial Chemotherapy (2001) 47, 61-66
© 2001 The British Society for Antimicrobial Chemotherapy
Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers
a Clinical Pharmacology Research Center, b Research Institute, and Departments of c Pharmacy and d Medicine, Bassett Healthcare, Cooperstown, NY, USA
*Correspondence address. Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326, USA. Tel: +1-607-547-3680; Fax: +1-607-547-6914; E-mail: guy.amsden{at}bassett.org
Owing to azithromycin's prolonged half-life, shorter and shorter dosage regimens are being studied for treatment of respiratory tract infections. Previous studies have concluded that the 3 and 5 day (1.5 g total) regimens not only provide at least equal serum and WBC exposures but also equal efficacy rates. An earlier clinical study using the entire 1.5 g dose at once or the current 3 day regimen in patients with atypical pneumonia noted equal efficacy. Similar trials are currently underway in both adult and paediatric populations. The goal of the present study was to investigate whether there were equal serum and WBC exposures when azithromycin was dosed as the current 3 day regimen or as a single large dose. Equal exposures would help validate future clinical trials of single dose regimens. Twelve healthy volunteers received both azithromycin regimens (1.5 g single dose and 500 mg/day for 3 days) in random order. Serum and WBC samples were collected at baseline and repeatedly for 10 days following the first dose of each regimen. Serum samples were assayed via HPLC (CV% < 10) and WBC samples via liquid chromatography/mass spectrometry (CV% < 10). Data were modelled using noncompartmental methods. Statistics were via ANOVA with significance defined as P < 0.05. All subjects completed both regimens with minimal incidence of adverse effects. Serum data [mean (range)] demonstrated no significant difference in exposure between the two regimens [single 13.1 (3.02–20.6) mg•h/L versus 3 day 11.2 (2.98–24.5) mg•h/L: P = 0.12], although it favoured the shorter regimen. WBC results demonstrated much higher exposures than seen with serum, but no significant difference between the two regimens was identified. These results suggest that a single oral 1.5 g regimen of azithromycin for respiratory tract infections should provide exposure at least equal to currently approved treatment regimens.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. McCormack, S. Bell, S. Senini, K. Walmsley, K. Patel, C. Wainwright, D. Serisier, M. Harris, and S. Bowler Daily versus weekly azithromycin in cystic fibrosis patients Eur. Respir. J., September 1, 2007; 30(3): 487 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. AMSDEN, T. B. GREGORY, C. A. MICHALAK, P. GLUE, and C. A. KNIRSCH PHARMACOKINETICS OF AZITHROMYCIN AND THE COMBINATION OF IVERMECTIN AND ALBENDAZOLE WHEN ADMINISTERED ALONE AND CONCURRENTLY IN HEALTHY VOLUNTEERS Am J Trop Med Hyg, June 1, 2007; 76(6): 1153 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Liu, H. Allaudeen, R. Chandra, K. Phillips, A. Jungnik, J. D. Breen, and A. Sharma Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen Antimicrob. Agents Chemother., January 1, 2007; 51(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beringer, K. M. T. Huynh, J. Kriengkauykiat, L. Bi, N. Hoem, S. Louie, E. Han, T. Nguyen, D. Hsu, P. A. Rao, et al. Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5013 - 5017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Girard, S. M. Finegan, M. W. Dunne, and M. E. Lame Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models J. Antimicrob. Chemother., August 1, 2005; 56(2): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Law and G. W Amsden Single-Dose Azithromycin for Respiratory Tract Infections Ann. Pharmacother., March 1, 2004; 38(3): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Danesi, A. Lupetti, C. Barbara, E. Ghelardi, A. Chella, T. Malizia, S. Senesi, C. A. Angeletti, M. Del Tacca, and M. Campa Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg J. Antimicrob. Chemother., April 1, 2003; 51(4): 939 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.A. Ioannidis, D. G. Contopoulos-Ioannidis, P. Chew, and J. Lau Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections J. Antimicrob. Chemother., November 1, 2001; 48(5): 677 - 689. [Abstract] [Full Text] [PDF]
|
|